View Older Stories View More Recent Stories

Mar 5, 2019 04:05PM Jazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
Feb 26, 2019 04:05PM Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results
Feb 14, 2019 04:42PM Jazz Pharmaceuticals (JAZZ) Announces Anne O'Riordan to Board
Feb 14, 2019 04:05PM Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors
Feb 12, 2019 04:05PM Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019
Jan 3, 2019 04:18PM Jazz Pharmaceuticals (JAZZ), Codiak BioSciences Enters Strategic Collaboration for Engineered Exosomes
Jan 3, 2019 04:05PM Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers
Dec 21, 2018 07:03AM Jazz Pharmaceuticals (JAZZ) Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness
Dec 21, 2018 07:00AM Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Dec 19, 2018 04:05PM Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 7
Dec 10, 2018 04:10PM Jazz Pharmaceuticals (JAZZ) Approves $400 Million Increase in Buyback Program
Dec 10, 2018 04:10PM Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million
Nov 29, 2018 08:06AM Jazz Pharmaceuticals (JAZZ) Reports First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for Treatment of Idiopathic Hypersomnia
Nov 29, 2018 08:00AM Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
Nov 28, 2018 08:00AM Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting
Nov 7, 2018 04:05PM Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Nov 6, 2018 04:05PM Jazz Pharmaceuticals Announces Third Quarter 2018 Financial Results
Oct 29, 2018 08:07AM Jazz (JAZZ) Announces FDA Approval of Xyrem for Treatment of Cataplexy or EDS in Pediatric Narcolepsy Patients
Oct 29, 2018 08:00AM Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Oct 23, 2018 04:05PM Jazz Pharmaceuticals to Report 2018 Third Quarter Financial Results on November 6, 2018
Oct 10, 2018 08:00AM Jazz Pharmaceuticals Survey Highlights Significant Impact of Excessive Daytime Sleepiness Related to Sleep Apnea
Sep 11, 2018 04:05PM Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch
Aug 29, 2018 04:05PM Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Aug 27, 2018 05:50AM Jazz Pharmaceuticals (JAZZ) Announces European Union Marketing Authorization for Vyxeos
Aug 27, 2018 02:00AM Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Aug 7, 2018 04:05PM Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results
Aug 6, 2018 04:15PM Jazz Pharmaceuticals and MD Anderson Cancer Center Collaborate to Evaluate Potential Treatment Options for Hematologic Malignancies
Aug 3, 2018 08:06AM Jazz Pharmaceuticals (JAZZ) Says CMS Granted New Technology Add-On Payment to Vyxeos Liposome for Injection
Aug 3, 2018 08:00AM CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection
Jul 24, 2018 04:05PM Jazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018
Jul 19, 2018 04:46PM Jazz Pharmaceuticals (JAZZ) Says Journal of Clinical Oncology published pivotal Phase 3 data for its Vyxeos Liposome for Injection
Jul 19, 2018 04:45PM Journal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmaceuticals' Vyxeos® (daunorubicin and cytarabine) Liposome for Injection
Jun 29, 2018 04:07PM Jazz Pharmaceuticals (JAZZ) Reports Agreement with TerSera Therapeutics LLC for Prialt
Jun 29, 2018 04:05PM Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt
Jun 29, 2018 08:18AM Jazz Pharmaceuticals (JAZZ) Reports Positive Opinion from European CHMP for Vyxeos for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Jun 29, 2018 08:15AM Vyxeos™ Receives Positive CHMP Opinion for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Jun 27, 2018 04:24PM Jazz Pharmaceuticals (JAZZ) Announces FDA Acceptance of sNDA for Xyrem to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jun 27, 2018 04:15PM Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jun 6, 2018 04:05PM Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference
Jun 4, 2018 06:26AM Jazz Pharmaceuticals (JAZZ) Announces Long-Term Safety & Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol
Jun 4, 2018 06:24AM Jazz Pharmaceuticals (JAZZ) Reports Long-Term Safety and Efficacy Data for Xyrem (sodium oxybate) in Pediatric Patients
Jun 3, 2018 05:00PM Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy
Jun 3, 2018 05:00PM Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea
May 31, 2018 08:30AM New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea
May 24, 2018 04:05PM Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS
May 10, 2018 08:30AM Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting
May 9, 2018 04:05PM Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences
May 8, 2018 04:05PM Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results
May 1, 2018 08:36AM Jazz Pharmaceuticals (JAZZ) Reports Supplemental NDA Filling for Xyrem (sodium oxybate)
May 1, 2018 08:30AM Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
View More Recent Stories View Older Stories